NCT04334863View on ClinicalTrials.gov

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions
Brain TumorMedulloblastomaBrain Metastases
Interventions
DRUG

WP1066

"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."

Trial Locations (1)

30322

Children's Healthcare of Atlanta (CHOA), Atlanta

All Listed Sponsors
collaborator

CURE Childhood Cancer, Inc.

OTHER

collaborator

Peach Bowl LegACy Fund

UNKNOWN

lead

Emory University

OTHER

NCT04334863 - WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors | Biotech Hunter | Biotech Hunter